Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2019, Article ID 7890673, 5 pages
https://doi.org/10.1155/2019/7890673
Case Report

Mesenchymal Stem Cell Therapy Overcomes Steroid Resistance in Severe Gastrointestinal Acute Graft-Versus-Host Disease

1Department of Pediatrics, Ehime University Graduate School of Medicine, Ehime, Japan
2Department of Pediatrics, Ehime Prefectural Central Hospital, Ehime, Japan

Correspondence should be addressed to Kozo Nagai; pj.ca.u-emihe.m@uozuok

Received 24 March 2019; Accepted 14 May 2019; Published 21 May 2019

Academic Editor: Janez Jazbec

Copyright © 2019 Kyoko Moritani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. D. Thomas, C. D. Buckner, M. Banaji et al., “One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation,” Blood, vol. 49, pp. 511–533, 1977. View at Google Scholar
  2. J. R. Passweg, H. Baldomero, P. Bader et al., “Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants,” Bone Marrow Transplantation, vol. 50, no. 4, pp. 476–482, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. H. J. Deeg, “How I treat refractory acute GVHD,” Blood, vol. 109, no. 10, pp. 4119–4126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. T. van Lint, C. Uderzo, A. Locasciulli et al., “Early treatment of acute graft-versus-host disease with high- or low- dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation,” Blood, vol. 92, no. 7, pp. 2288–2293, 1998. View at Google Scholar · View at Scopus
  5. L. Cragg, B. R. Blazar, T. Defor et al., “A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 6, no. 4, pp. 441–447, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Patriarca, A. Sperotto, D. Damiani et al., “Infliximab treatment for steroid-refractory acute graft-versus-host disease,” Haematologica, vol. 89, no. 11, pp. 1352–1359, 2004. View at Google Scholar · View at Scopus
  7. O. N. Koç, S. L. Gerson, B. W. Cooper et al., “Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy,” Journal of Clinical Oncology, vol. 18, no. 2, pp. 307–316, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Frassoni, M. Labopin, A. Bacigalupo et al., “Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft-versus-host disease: a matched pair analysis,” Bone Marrow Transplantation, vol. 29, supplement 2, 2002. View at Google Scholar
  9. K. Le Blanc, I. Rasmusson, B. Sundberg et al., “Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells,” The Lancet, vol. 363, no. 9419, pp. 1439–1441, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Le Blanc, F. Frassoni, L. Ball et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” The Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Cetin, G. Akyol, Z. B. Gonen et al., “Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GvHD patients,” Bone Marrow Transplantation, vol. 52, no. 5, pp. 783–785, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Zhao, R. Lou, F. Huang et al., “Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 21, no. 1, pp. 97–104, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. G. M. Dotoli, G. C. De Santis, M. D. Orellana et al., “Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation,” Bone Marrow Transplantation, vol. 52, no. 6, pp. 859–862, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Penack, E. Henke, D. Suh et al., “Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth,” JNCI: Journal of the National Cancer Institute, vol. 102, no. 12, pp. 894–908, 2010. View at Publisher · View at Google Scholar
  15. L. Schwab, L. Goroncy, S. Palaniyandi et al., “Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage,” Nature Medicine, vol. 20, pp. 648–654, 2014. View at Google Scholar
  16. K. Reinhardt, D. Foell, T. Vogl et al., “Monocyte-induced development of th17 cells and the release of s100 proteins are involved in the pathogenesis of graft-versus-host disease,” The Journal of Immunology, vol. 193, no. 7, pp. 3355–3365, 2014. View at Publisher · View at Google Scholar
  17. G. R. Hill and J. L. M. Ferrara, “The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation,” Blood, vol. 95, no. 9, pp. 2754–2759, 2000. View at Google Scholar · View at Scopus
  18. C. Castilla-Llorente, P. J. Martin, G. B. McDonald et al., “Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation,” Bone Marrow Transplantation, vol. 49, no. 7, pp. 966–971, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Möricke, M. Zimmermann, A. Reiter et al., “Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000,” Leukemia, vol. 24, no. 2, pp. 265–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Robak, J. Zambonelli, J. Bilinski, and G. W. Basak, “Diarrhea after allogeneic stem cell transplantation: Beyond graft-versus-host disease,” European Journal of Gastroenterology & Hepatology, vol. 29, no. 5, pp. 495–502, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Muroi, K. Miyamura, M. Okada et al., “Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study,” International Journal of Hematology, vol. 103, no. 2, pp. 243–250, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Martin, J. Uberti, R. Soiffer et al., “Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD,” Biology of Blood and Marrow Transplantation, vol. 16, no. 2, pp. S169–S170, 2010. View at Publisher · View at Google Scholar
  23. L. M. Ball, M. E. Bernardo, H. Roelofs et al., “Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease,” British Journal of Haematology, vol. 163, no. 4, pp. 501–509, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. V. K. Prasad, K. G. Lucas, G. I. Kleiner et al., “Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study,” Biology of Blood and Marrow Transplantation, vol. 17, no. 4, pp. 534–541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Horwitz, P. L. Gordon, W. K. Koo et al., “Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, pp. 8932–8937, 2002. View at Google Scholar
  26. A. Mahmood, D. Lu, M. Lu et al., “Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells,” Neurosurgery, vol. 53, no. 3, pp. 697–703, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. D. H. Fowler, K. Kurasawa, R. Smith, M. A. Eckhaus, and R. E. Gress, “Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus- host disease without impairing allogeneic engraftment in sublethally irradiated mice,” Blood, vol. 84, no. 10, pp. 3540–3549, 1994. View at Google Scholar · View at Scopus
  28. S. Aggarwal and M. F. Pittenger, “Human mesenchymal stem cells modulate allogeneic immune cell responses,” Blood, vol. 105, no. 4, pp. 1815–1822, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Tatara, K. Ozaki, Y. Kikuchi et al., “Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation,” Cytotherapy, vol. 13, no. 6, pp. 686–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Ringdén, M. Uzunel, I. Rasmusson et al., “Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease,” Transplantation, vol. 81, no. 10, pp. 1390–1397, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Ringdén, M. Uzunel, B. Sundberg et al., “Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon,” Leukemia, vol. 21, no. 11, pp. 2271–2276, 2007. View at Publisher · View at Google Scholar · View at Scopus